2023 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
October 5, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On October 5, 2023, the committee will meet in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2024 Southern Hemisphere Influenza Season.
June 15, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On June 15, 2023, the committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign. This discussion will include consideration of the vaccine composition for fall to winter, 2023-2024.
May 18, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.
March 7, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On March 7, 2023, the committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2023--2024 influenza season.
February 28 - March 1, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On February 28, 2023, under Topic 1, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125769 (STN 125769/0), for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older.
On March 1, 2023, under Topic 2, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of AREXVY (Respiratory Syncytial Virus Vaccine, Recombinant, Adjuvanted), manufactured by GSK, with a requested indication, in BLA 125775 (STN 125775/0), for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older.
January 26, 2023
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
The committee will meet in open session to discuss the future vaccination regimens addressing COVID-19.